FDA approves Pfizer and Moderna boosters for all US adults
November 22, 2021Sales and Marketing
The FDA and CDC have cleared the Pfizer and Moderna booster jabs for adults, after reviewing new data supporting the …
FDA accept New Drug Application for Obseva’s linzagolix
November 22, 2021Sales and Marketing
Obseva, a biopharmaceutical company developing and commercialising novel therapies to improve reproductive health, have announced that the NDA for linzagolix …
Novel mechanisms could transform standards of care in multiple cancers, MS, and Lupus
November 22, 2021Sales and Marketing
Leading science and technology company, Merck KGaA, Darmstadt, Germany have identified five mid- to late-stage assets with first-in-class potential for …
Scientists uncover factors influencing waning immunity with Pfizer COVID-19 vaccine
November 22, 2021Sales and Marketing
Scientists have discovered multiple factors influencing declining immunity over time with the Pfizer COVID-19 vaccine, according to News Medical.
Pfizer seek EUA for novel COVID treatment pill
November 19, 2021Medical Communications
Pfizer is seeking FDA Emergency Use Authorisation (EUA) for the novel oral antiviral, Paxlovid. The pill, if authorised, will help …
ImmunityBio expands COVID-19 vaccine programme to incorporate ‘mix-and-match’ technologies
November 19, 2021Medical Communications
Clinical-stage immunotherapy company, ImmunityBio Inc, has announced the expansion of the company’s cancer and infectious disease vaccine programmes to include …
FDA approve Keytruda as adjuvant treatment for kidney cancer
November 19, 2021Medical Communications
The FDA has approved Keytruda® for the treatment of patients with early renal cell carcinoma at high or intermediate-high risk …
NICE recommends at-home treatment for spinal muscular atrophy
November 19, 2021Medical Communications
NICE has recommended risdiplam as treatment for the rare genetic disorder, spinal muscular atrophy, as part of a managed access …
Crohn’s patients see 65% remission in clinical trial
November 18, 2021Business Services
Janssen has announced topline results from the Phase II GALAXI 1 clinical which showed rates of clinical remission previously reported …
NIAID and Children’s National Hospital begin long-term study of children with COVID-19
November 18, 2021Business Services
The National Institutes of Health has commenced a long-term investigation into the impacts of COVID-19 in children. The study, supported …
AstraZeneca COVID-19 antibody drug offers 83% protection over six month period
November 18, 2021Business Services
New data from AstraZeneca’s COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials have revealed high efficacy from a …
NICE recommends Opdivo (nivolumab) for oesophageal cancer treatment
November 17, 2021Research and Development
NICE has recommended nivolumab for the adjuvant treatment of completely resected oesophageal or gastro-oesophageal junction (GOJ) cancer, in adults who …
Health experts warn of a ‘hidden pandemic’ of antibiotic-resistant infections
November 17, 2021Research and Development
UK health officials have warned that a ‘hidden pandemic’ of antibiotic-resistant infections could occur if people take antibiotics to fight …
Pfizer deal allows generic versions of COVID pill for low-income countries
November 17, 2021Research and Development
Pfizer has announced a deal for the production of its antiviral Paxlovid pill to generic drug manufactures, for supply in …
US secures over 750,000 doses of GSK-Vir COVID-19 drug
November 17, 2021Research and Development
The US has secured GSK and Vir Biotechnology’s antibody-based COVID-19 treatment, through signing contracts worth approximately $1 billion, according to …
Orexo’s new drug effective against opioid overdoses
November 16, 2021Manufacturing and Production
Orexo announced it has successfully completed the trial for its lead pharmaceutical pipeline asset, OX124, designed to help patients in …
Moderna announce promising study in mRNA drug for heart failure
November 16, 2021Manufacturing and Production
The biotechnology company Moderna have announced positive data from the AstraZeneca-led Phase IIa EPICCURE trial, evaluating the use of a …
Revelar Biotherapeutics launches for development of COVID-19 and other antibody therapeutics
November 16, 2021Manufacturing and Production
Twist Bioscience Corporation announced that it has launched Revelar Biotherapeutics, an independently operated, new biotechnology company to develop and commercialise …
Arrowhead Collaboration presents Phase IIb data from Hepatitis B study
November 16, 2021Manufacturing and Production
Arrowhead Pharmaceuticals Inc collaborator, Janssen Pharmaceuticals Inc, have presented clinical data from REEF-1, a Phase IIb study of different combination …
Emergex trial new form of COVID vaccine
November 15, 2021Sales and Marketing
Emergex, an Oxfordshire based company, is moving towards Phase I trials for its novel COVID-19 vaccine, which is applied as …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
